Cost saving opportunities need to be balanced with physician and patient values; savings should be re-invested into new oncology therapies.
OTTAWA, ON – May 7, 2019 - Biologic treatments have been approved and used in Canada for several decades, marking the beginning of an exciting time for the treatment of many diseases as these therapies truly changed the outcomes for many patients living with chronic and often fatal diseases. As patents expire on biologic products, biosimilar products have become available, with several oncology biosimilars currently being assessed by various regulatory agencies.
Given that patents are expiring on various breast cancer treatments, the Canadian Breast Cancer Network (CBCN) wanted to ensure that the perspectives of physicians and breast cancer patients were considered as policies around the implementation of biosimilars are being developed. Through consultation with physicians and patients, CBCN has outlined five key recommendations for consideration when implementing biosimilars in oncology:
Read the full "Biosimilars & Breast Cancer" white paper for further details around the perspectives and values of physicians and patients.
Jenn Gordon, Director of Operations
Canadian Breast Cancer Network
613-230-3044 ext. 255
Published on newswire.ca